S 1269 · 118th Congress 2023–2025, ended

INSULIN Act of 2023

Latest action · Apr 25, 2023 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedApr 25, 2023
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2023 or the INSULIN Act of 2023

This bill limits cost-sharing for insulin under private health insurance and revises the requirements for approval and cost-sharing of generic drugs and biosimilar products.

Specifically, the bill caps cost-sharing under private health insurance for a month's supply of selected insulin products at $35 or 25% of a plan's negotiated price (after any price concessions), whichever is less, beginning in 2025.

The bill also requires pharmacy benefit managers (PBMs) to remit to the group health plan 100% of the fees, alternative discounts, and all other remuneration received from a drug manufacturer.

Additionally, the bill modifies the Food and Drug Administration's (FDA) procedures for determining whether a petition to delay the approval of a generic drug was made with the primary purpose of delaying the application and provides for the referral of such petitions to the Federal Trade Commission. The bill also authorizes the FDA to expedite the development and review of applications for products designated as a competitive biosimilar therapy.

Finally, the bill permits prescription drug plan sponsors under Medicare Part D to make certain mid-year changes to the cost-sharing tier of a reference biological product if the sponsor also adds the respective biosimilar product to the same or a lower cost-sharing tier as the reference biological product immediately prior to the change.

Cosponsors 13

Members who signed on, in the order they did. Signatures ran from Apr 25, 2023 to Nov 9, 2023; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
R-MESusan M. CollinsOriginalApr 25, 2023
D-MIDebbie StabenowJun 22, 2023
D-MTJon TesterJun 22, 2023
R-ALKatie Boyd BrittJun 22, 2023
R-ALTommy TubervilleJun 22, 2023
D-AZMark KellySep 19, 2023
R-MSRoger F. WickerSep 19, 2023
D-NVJacky RosenOct 4, 2023
R-AKLisa MurkowskiOct 4, 2023
I-MEAngus S. King Jr.Nov 2, 2023
R-INMike BraunNov 2, 2023
R-IAChuck GrassleyNov 9, 2023
D-WITammy BaldwinNov 9, 2023

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateHealth, Education, Labor, and Pensions Committee
Referred Apr 25, 2023

Actions 2

Everything that happened, newest first.

  1. Apr 25, 2023Introduced in Senate
  2. Apr 25, 2023Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

In the Congressional Record 2

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
SenateDebate and remarks S6708, S6709Jeanne Shaheen D-NH, Susan M. Collins R-MENov 21, 2024
SenateDebate and remarks S1332–S1334Jeanne Shaheen D-NH, Susan M. Collins R-MEApr 25, 2023

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Printed hearings 1

Hearings whose printed record names this bill, newest first: hearings on it, and wider hearings where it came up.

NumberHearingCommitteeHeld
S. Hrg. 118-211WHAT IS FUELING THE DIABETES EPIDEMIC?89 pagesHealth, Education, Labor, and Pensions CommitteeDec 14, 2023

Related bills 2

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 1067Ensuring Timely Access to Generics Act of 2023Related billJun 22, 2023
HR 5372Expanding Seniors' Access to Lower Cost Medicines Act of 2023Related billDec 6, 2023

Titles 3

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to reduce the price of insulin and provide for patient protections with respect to the cost of insulin.
Short Title(s) as Introduced
INSULIN Act of 2023
Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2023

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Apr 25, 2023Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.